

George R Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11169274/publications.pdf>

Version: 2024-02-01

96
papers

9,675
citations

61687

45
h-index

46524

93
g-index

100
all docs

100
docs citations

100
times ranked

9177
citing authors

#	ARTICLE	IF	CITATIONS
1	Coccidioidal Peritonitis: A Review of 17 Cases. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac017.	0.4	2
2	Sex Differences in Susceptibility to Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab543.	0.4	12
3	Human Immunodeficiency Virus-1 Latency Reversal via the Induction of Early Growth Response Protein 1 to Bypass Protein Kinase C Agonist-Associated Immune Activation. <i>Frontiers in Microbiology</i> , 2022, 13, 836831.	1.5	4
4	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	25
5	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non- <i>fumigatus</i>): A multicentre, non-interventional registry study. <i>Mycoses</i> , 2022, 65, 186-198.	1.8	7
6	Let's talk about sex characteristics" As a risk factor for invasive fungal diseases. <i>Mycoses</i> , 2022, 65, 599-612.	1.8	25
7	Characterization of the Growth and Morphology of a BSL-2 <i>Coccidioides posadasii</i> Strain That Persists in the Parasitic Life Cycle at Ambient CO ₂ . <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 455.	1.5	0
8	Cryptococcosis among hospitalised patients with COVID-19: A multicentre research network study. <i>Mycoses</i> , 2022, 65, 815-823.	1.8	14
9	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e3647-e3655.	2.9	75
10	Investigation of nosocomial SARS-CoV-2 transmission from two patients to healthcare workers identifies close contact but not airborne transmission events. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1046-1052.	1.0	21
11	Do high MICs predict the outcome in invasive fusariosis?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1063-1069.	1.3	28
12	Invasive infections with <i>Purpureocillium lilacinum</i> : clinical characteristics and outcome of 101 cases from FungiScope® and the literature. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1593-1603.	1.3	18
13	Clinical performance of a point-of-care <i>Coccidioides</i> antibody test in dogs. <i>Journal of Veterinary Internal Medicine</i> , 2021, 35, 965-969.	0.6	6
14	Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
15	Aspergillosis. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 415-434.	1.9	96
16	Coccidioidomycosis. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 453-469.	1.9	35
17	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e364-e374.	4.6	99
18	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	1.3	15

#	ARTICLE	IF	CITATIONS
19	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. <i>Drugs</i> , 2021, 81, 1703-1729.	4.9	168
20	Aspergillus Infections. <i>New England Journal of Medicine</i> , 2021, 385, 1496-1509.	13.9	74
21	Coronavirus Disease 2019-associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab510.	0.4	75
22	Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism. <i>Clinical Infectious Diseases</i> , 2020, 70, 2593-2598.	2.9	68
23	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
24	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	1.9	83
25	Breakthrough invasive fungal infections: Who is at risk?. <i>Mycoses</i> , 2020, 63, 1021-1032.	1.8	94
26	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	1.7	20
27	Differential Thermotolerance Adaptation between Species of <i>Coccidioides</i> . <i>Journal of Fungi (Basel)</i> , 2021, 7, 1078-1083.	1.5	13
28	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. <i>Medical Mycology</i> , 2020, 58, 569-578.	0.3	1
29	Leukoerythroblastic reaction in a patient with COVID-19 infection. <i>American Journal of Hematology</i> , 2020, 95, 999-1000.	2.0	85
30	Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. <i>Journal of Fungi (Basel)</i> , 2021, 7, 1078-1083.	1.5	13
31	Defining breakthrough invasive fungal infection—Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. <i>Mycoses</i> , 2019, 62, 716-729.	1.8	129
32	The Rise of <i>Coccidioides</i> : Forces Against the Dust Devil Unleashed. <i>Frontiers in Immunology</i> , 2019, 10, 2188.	2.2	37
33	Fungal Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patients. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 545-566.	1.9	25
34	Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate. <i>JCI Insight</i> , 2019, 4, .	2.3	18
35	Current Concepts and Future Directions in the Pharmacology and Treatment of <i>Coccidioidomycosis</i> . <i>Medical Mycology</i> , 2019, 57, S76-S84.	0.3	50
36	Population Structure and Genetic Diversity among Isolates of <i>Coccidioides posadasii</i> in Venezuela and Surrounding Regions. <i>MBio</i> , 2019, 10, .	1.8	28

#	ARTICLE	IF	CITATIONS
37	Isavuconazole in the Treatment of Coccidioidal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	27
38	Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	6
39	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1981-1989.	2.9	120
40	Dating the <i>Cryptococcus gattii</i> Dispersal to the North American Pacific Northwest. <i>MSphere</i> , 2018, 3, .	1.3	20
41	<i>Coccidioides immitis</i> and <i>Coccidioides posadasii</i> (Coccidioidomycosis). , 2018, , 1276-1282.e2.		0
42	Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation. <i>Mycoses</i> , 2018, 61, 337-339.	1.8	25
43	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018, 66, 1678-1686.	2.9	129
44	Novel approaches to antifungal therapy. <i>American Journal of Transplantation</i> , 2018, 18, 287-288.	2.6	3
45	Coccidioidomycosis Complement Fixation Titer Trends in the Age of Antifungals. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	40
46	Flucytosine resistance in <i>Cryptococcus gattii</i> is indirectly mediated by the FCY2-FCY1-FUR1 pathway. <i>Medical Mycology</i> , 2018, 56, 857-867.	0.3	18
47	HIV latency is reversed by ACSS2-driven histone crotonylation. <i>Journal of Clinical Investigation</i> , 2018, 128, 1190-1198.	3.9	109
48	HIV Exploits Antiviral Host Innate GCN2-ATF4 Signaling for Establishing Viral Replication Early in Infection. <i>MBio</i> , 2017, 8, .	1.8	19
49	Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis. <i>Clinical Infectious Diseases</i> , 2017, 65, 338-341.	2.9	19
50	<i>In Vivo</i> 11 β -Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	37
51	Favorable Outcome in <i>Coccidioides Endophthalmitis</i> —A Combined Medical and Surgical Treatment Approach. <i>Cornea</i> , 2017, 36, 1423-1425.	0.9	5
52	Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. <i>Infection and Drug Resistance</i> , 2016, 9, 79.	1.1	54
53	Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. <i>Journal of Fungi (Basel)</i> , 2016, 1, 1-15.	1.5	10
54	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, e1-e60.	2.9	1,861

#	ARTICLE	IF	CITATIONS
55	Local Population Structure and Patterns of Western Hemisphere Dispersal for <i>Coccidioides</i> spp., the Fungal Cause of Valley Fever. <i>MBio</i> , 2016, 7, e00550-16.	1.8	71
56	Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. <i>Clinical Infectious Diseases</i> , 2016, 63, 356-362.	2.9	167
57	Endemic Mycoses: What's New About Old Diseases?. <i>Current Clinical Microbiology Reports</i> , 2016, 3, 71-80.	1.8	8
58	Pharmacokinetics of voriconazole after intravenous and oral administration to healthy cats. <i>American Journal of Veterinary Research</i> , 2016, 77, 931-939.	0.3	17
59	Update on the Epidemiology of Coccidioidomycosis. <i>Current Fungal Infection Reports</i> , 2016, 10, 141-146.	0.9	5
60	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet, The</i> , 2016, 387, 760-769.	6.3	695
61	Invasive Aspergillosis. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 125-142.	1.9	97
62	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 828-837.	4.6	528
63	Coccidioidomycosis. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 229-246.	1.9	147
64	Mycotic Infections Acquired outside Areas of Known Endemicity, United States. <i>Emerging Infectious Diseases</i> , 2015, 21, 1935-1941.	2.0	73
65	<i>Coccidioides</i> Endospores and Spherules Draw Strong Chemotactic, Adhesive, and Phagocytic Responses by Individual Human Neutrophils. <i>PLoS ONE</i> , 2015, 10, e0129522.	1.1	51
66	Call for a California Coccidioidomycosis Consortium to Face the Top Ten Challenges Posed by a Recalcitrant Regional Disease. <i>Mycopathologia</i> , 2015, 179, 1-9.	1.3	24
67	Coccidioidomycosis: Recent Updates. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 746-755.	0.8	46
68	Valley Fever: Finding New Places for an Old Disease: <i>Coccidioides immitis</i> Found in Washington State Soil Associated With Recent Human Infection. <i>Clinical Infectious Diseases</i> , 2015, 60, e1-e3.	2.9	153
69	Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF- κ B Signaling in Combination with JQ1 Induced p-TEFb Activation. <i>PLoS Pathogens</i> , 2015, 11, e1005066.	2.1	175
70	<i>Cryptococcus gattii</i> in North American Pacific Northwest: Whole-Population Genome Analysis Provides Insights into Species Evolution and Dispersal. <i>MBio</i> , 2014, 5, e01464-14.	1.8	126
71	Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C β -NF- κ B signaling. <i>Aids</i> , 2014, 28, 1555-1566.	1.0	83
72	Phenotypic Differences of <i>Cryptococcus</i> Molecular Types and Their Implications for Virulence in a <i>Drosophila</i> Model of Infection. <i>Infection and Immunity</i> , 2014, 82, 3058-3065.	1.0	33

#	ARTICLE	IF	CITATIONS
73	Fungal infections of the skin and nail: new treatment options. Expert Review of Anti-Infective Therapy, 2014, 12, 1389-1405.	2.0	21
74	Fungal Disease of the Nose and Sinuses: An Updated Overview. Current Allergy and Asthma Reports, 2013, 13, 152-161.	2.4	26
75	Amphotericin B-Impregnated Bone Cement To Treat Refractory Coccidioidal Osteomyelitis. Antimicrobial Agents and Chemotherapy, 2013, 57, 6341-6343.	1.4	10
76	Coccidioidomycosis Acquired in Washington State. Clinical Infectious Diseases, 2013, 56, 847-850.	2.9	102
77	Coccidioidomycosis: epidemiology. Clinical Epidemiology, 2013, 5, 185.	1.5	216
78	Fluoride Excess in Coccidioidomycosis Patients Receiving Long-Term Antifungal Therapy: an Assessment of Currently Available Triazoles. Antimicrobial Agents and Chemotherapy, 2012, 56, 563-564.	1.4	46
79	A murine model of <i>Cryptococcus gattii</i> meningoencephalitis. Journal of Antimicrobial Chemotherapy, 2012, 67, 1432-1438.	1.3	25
80	Fungal disease of the nose and paranasal sinuses. Journal of Allergy and Clinical Immunology, 2012, 129, 321-326.	1.5	103
81	Update on the optimal use of voriconazole for invasive fungal infections. Infection and Drug Resistance, 2011, 4, 43.	1.1	61
82	Pulmonary Aspergillosis: Recent Advances. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 673-681.	0.8	38
83	Pulmonary Coccidioidomycosis. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 754-763.	0.8	103
84	Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole. Mycopathologia, 2010, 170, 291-313.	1.3	118
85	Voriconazole use and pharmacokinetics in combination with interferon- β for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Medical Mycology, 2010, 48, 532-536.	0.3	20
86	Invasive Aspergillosis after Pandemic (H1N1) 2009. Emerging Infectious Diseases, 2010, 16, 971-973.	2.0	80
87	Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 109, 488-495.	1.6	134
88	In vitro activity of isavuconazole against <i>Trichosporon</i> , <i>Rhodotorula</i> , <i>Geotrichum</i> , <i>Saccharomyces</i> and <i>Pichia</i> species. Journal of Antimicrobial Chemotherapy, 2009, 64, 79-83.	1.3	58
89	Antifungal Susceptibilities among Different Serotypes of <i>Cryptococcus gattii</i> and <i>Cryptococcus neoformans</i> . Antimicrobial Agents and Chemotherapy, 2009, 53, 309-311.	1.4	114
90	Pneumomachis caused by metastatic gas gangrene. Diagnostic Microbiology and Infectious Disease, 2009, 63, 108-110.	0.8	13

#	ARTICLE	IF	CITATIONS
91	Overview of Antifungal Agents. <i>Clinics in Chest Medicine</i> , 2009, 30, 203-215.	0.8	106
92	Evaluation of Etest Method for Determining Isavuconazole MICs against <i>Cryptococcus gattii</i> and <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2959-2961.	1.4	30
93	Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to <i>Candida glabrata</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3783-3785.	1.4	150
94	Pulmonary Aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 103-110.	0.8	55
95	HIV Infection Increases the Risk of Heparin-Induced Thrombocytopenia. <i>Clinical Infectious Diseases</i> , 2007, 45, 1393-1396.	2.9	19
96	<i>Histoplasma</i> , <i>Blastomyces</i> , <i>Coccidioides</i> , and Other Dimorphic Fungi Causing Systemic Mycoses. , 0 , 2109-2127.		5